

NeuroScientific

ASX:NSB

Patented Stem Cell Solutions for Complex Auto-Immune Disorders & Unmet Needs

Nathan Smith | Chief Executive Officer

01

Robust Profile & Strong Balance Sheet

~\$50M market cap with \$7.3M in cash², strong leadership team.

02

StemSmart™ Tech Platform

Method of manufacturing differentiated MSC with a global IP position.

03

Proven Clinical Efficacy

Strong safety profile and 78% overall response in refractory Crohn's trial¹.

04

Secure Supply Chain

Expanded manufacturing capacity through tech transfer with Q-Gen.

21 October 2025

1) ASX Announcement (16 April 2025) – "NeuroScientific to Acquire Leading Stem Cell Technology"

2) Annual Report & Appendix 4E (28 August 2025)

Strength in Leadership & Advisory

NeuroScientific



ROB MCKENZIE

LL.B; B.Juris, FAICD

NON-EXECUTIVE CHAIRMAN

- Lawyer with over 35 years' experience in corporate and commercial transactions, restructuring and dispute resolution
- Advised on M&A; IPOs; corporate structure; corporate governance; board and compliance, and financial structuring
- Chairman of the Perron Institute and was previously on the Takeovers Panel



DR ANTON UVAROV

PhD, MBA

NON-EXECUTIVE DIRECTOR

- Significant healthcare industry experience with a focus on neuroscience
- Former equities analyst for Citigroup and Co-Founder of several publicly-listed Australian companies (e.g., Dimerrix [ASX:DXB], Actinogen Medical [ASX:ACW], BlinkLab [ASX:BB1])
- Currently Executive Director at BlinkLab Limited (ASX:BB1)



PAUL FRY

BBus

NON-EXECUTIVE DIRECTOR

- Former Partner of Ernst & Young and PwC in Australia and Canada
- Expertise surrounding public markets, capital raisings, governance, risk management, and corporate transactions
- Consults to companies across various industries and has been involved with a number of publicly-listed ASX entities



CLARKE BARLOW

BCom, MAICD

NON-EXECUTIVE DIRECTOR

- Financial Advisor and Capital Markets Specialist with over 20 years' experience in financial services across Australia and the UK
- Extensive experience providing corporate advisory services for ASX-listed companies across various industries, with a focus on growth opportunities in biotechnology, technology, industrial, and resources.



NATHAN SMITH

BSc

CHIEF EXECUTIVE OFFICER

- Over 25 years' experience across biologics and cell & gene therapies
- Formerly at GlaxoSmithKline, Sanofi Genzyme, Mesoblast, BioReliance, and most recently Cell Therapies Pty Ltd leading business development



DR MARIAN STURM

FFSc (RCPA), PhD, MSc, BSc Hons

CHIEF SCIENTIFIC OFFICER

- Expert with 40 years' experience in research, operational and clinical development of cellular treatments
- Manufacturing of therapeutic goods for over 20 years, and was a member for TGA Advisory Committee on Biologics (2012-2022)



PROF CATHERINE COLE

MBBS, FRACP, FRCPA

CHIEF MEDICAL OFFICER

- 35 years experience in clinical paediatric haematology, oncology, clinical trials & stem cell transplantation
- Served on TGA Advisory Committee for Prescription Medicines & Pharmaceutical Benefits Advisory Committee (PBAC)

Introducing StemSmart™

NeuroScientific

The StemSmart™ MSC product is potent, efficacious and safe¹



StemSmart™ is a global patented technology resulting in differentiated MSC from others in product class



High-quality product is manufactured under StemSmart™ methodology in TGA-accredited facilities



Large number of patients treated with no serious adverse safety events reported



StemSmart™ performs best in diseases with HIGH to SEVERE inflammation, where conventional treatments have failed

US FDA Approval of MSCs Pathway to Commercialisation in US

The United States FDA's recent approval of the first MSC therapy² marks a significant milestone for the commercialisation of this product class.

This U.S. decision provides a direct roadmap for developers of MSC therapies to commercialise their product candidates and obtain global investment.

StemSmart™

1. ASX Announcement (16 April 2025) – “Neuroscientific to Acquire Leading Stem Cell Technology”

2. Mesoblast Limited ASX Announcement (19 December 2024) – “Mesoblast’s Ryoncil® is the First U.S. FDA-approved Mesenchymal Stromal Cell (MSC) Therapy”

Refractory Crohn's (Life-Threatening)

- **Unresponsive to conventional therapies**
(Antibiotics/Steroids/Biologics)
- **~30% patients become refractory**
- **Surgery is often the only option**

Fistulas

- **Sores or ulcers in gastrointestinal tract**
(create an abnormal passageway from the intestine to another organ or to outside surface of the body)
- **About 30% of Crohn's patients will develop fistulas**
- **Unresolved chronic inflammation**



6-8 million
People living with Crohn's
disease globally*



StemSmart™

Special Access Program (Commenced June 2025)

Crohn's Fistulas

Treat patients with Crohn's Fistulas on compassionate grounds

- ≤12 patients
- Non-healing fistulas
- Administration of StemSmart™ at weekly intervals, for 4 weeks
- Evaluation at 8-10 weeks

Clinical Response


- Closure of > 50% of all fistula openings in a patient or;
- > 50% reduction of fistula discharge in a patient

Next Steps

- Program results, including maintenance doses and dose timing, to inform future Phase 2 trial in refractory Crohn's disease

Key Milestones

NeuroScientific







○ Key Milestone or Potential News Flow Event

● Anticipated Clinical Trial Results

Product Pipeline & Market Size

Key Clinical Targets (StemSmart™ Addressable Markets)

		Global Market	Forecast Increase in Market
	Crohn's Disease	<ul style="list-style-type: none"> Need for more effective treatments with less side effects Require additional treatment option for patients who have failed all other medical therapies 	<p>US\$13.8 billion By 2026¹</p> <p>Increase from US\$9.0 billion in 2016</p> <p>53% from 2016</p>
	Kidney Transplant	<ul style="list-style-type: none"> Need rescue therapies for acute renal rejection Minimise rejection risk, while reducing toxicity Need to improve long term patient graft function and patient survival 	<p>US\$7.2 billion By 2030²</p> <p>(Organ transplant immuno-suppressants) Increase from US\$5.5 billion in 2024</p> <p>31% from 2014</p>
	Lung Disorders	<ul style="list-style-type: none"> No long-term effective treatment for COPD – results in airflow obstruction (obstructive bronchiolitis and emphysema) Lung Transplant Rejection Current treatments cumbersome, ineffective, terminal disease 	<p>US\$33 billion By 2034³</p> <p>Increase from US\$20 billion in 2024</p> <p>65% from 2024</p>
	GvHD	<ul style="list-style-type: none"> Patients may develop a severe and life-threatening condition after a bone marrow transplant Currently low rate of survival in severe refractory GVHD 	<p>US\$5.31 billion in 2032⁴</p> <p>Increase from US\$2.55 billion in 2023</p> <p>208% from 2023</p>

1. [Crohn's Disease: Dynamic Market Forecast to 2026](#)

2. [Grand View Research - Organ Transplant Immunosuppressant Drugs Market Size](#)

3. [PharmaPoint: Chronic Obstructive Pulmonary Disease – Global Drug Forecast Market Analysis to 2025 – *for organ transplant immuno-suppressants](#)

4. [Global Graft versus Host Disease \(GVHD\) Market 2019-2029](#)


Securing the StemSmart™ Supply Chain

NeuroScientific

Partnership with Q-Gen Cell Therapeutics¹

- Tech transfer has been initiated for NSB's patented manufacturing process with targeting Phase 2 clinical trial supply by 2H CY 2026.
- Q-Gen has a 13-cleanroom facility that has been licensed by the TGA for manufacturing, testing and release for supply of clinical products.
- With over 25 years' experience in cell therapy manufacturing supporting industry, Q-Gen has the capacity and capability to support NSB's clinical and commercial objectives.

Patented StemSmart™ Manufacturing Process



1. ASX announcement 31 July 2025 - "NeuroScientific Partners with Leading Biologic Manufacturer"

The Vision for Stem Cell Therapies...

NeuroScientific



Global Crohn's Solution for Unmet Medical Need



Over 6 Million people are living with Crohn's globally (over 1 million in US alone) with over 30% not responding to conventional treatment including blockbuster biologics.



Patented Platform

StemSmart™



Significant potential across use cases, with a proprietary Mesenchymal Stem Cell (MSC) technology that enhances safety, efficacy, and manufacturing consistency.



Programs Underway & Demonstrated Potential



Special Access Program for Fistulising Crohn's Disease underway with previous Phase 2 trial achieving 78% overall response rate in Refractory Crohn's¹ and future global Phase 2 trial planned for late 2026.



Expansion to High-Value Therapeutic Indications



MSC therapy validated by US FDA approval² and targeting large, high-growth markets such as Crohn's Disease, Kidney Transplant, Lung Disorders, and more – a significant total market across all indications (US \$35 – 40 million).

What's Next?

Phase 2 is in sight...

The Crohn's Special Access Program is underway, paving the way for a global Phase 2 trial in 2026.

Indications Expanding...

StemSmart™ is applicable to kidney transplant, GvHD, and lung disorders, and more – unlocking broad therapeutic markets.

Manufacturing Secured

GMP process transfer to Q-Gen enables scaling for clinical trials and future commercialisation.

1) ASX Announcement (16 April 2025) - "NeuroScientific to Acquire Leading Stem Cell Technology"

2) Mesoblast Limited ASX Announcement (19 December 2024) – "Mesoblast's Ryoncil® is the First U.S. FDA-approved Mesenchymal Stromal Cell (MSC) Therapy"

Audience Q&A

Nathan Smith

Chief Executive Officer

+61 477 738 404

nsmith@neuroscientific.com

Dr Anton Uvarov

Founding Non-Executive Director

+61 8 6268 2641

au@neuroscientific.com

NeuroScientific

ASXNSB

Appendix

Company Overview

NeuroScientific

Corporate Share Information

As at 10 October 2025

SHARE PRICE	A\$0.15
MARKET CAPITALISATION	~A\$49.89 million

Capital Structure & Cash On Hand

	ORDINARY SHARES	PERFORMANCE SHARES	OPTIONS
CAPITAL	333.2 million	57.1 million	45.25 million
CASH	~\$7.3 million		

Share Price Chart

As at 10 October 2025



Presentation Information

This presentation has been prepared by NeuroScientific Biopharmaceuticals Ltd (ASX: NSB) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision.

This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in NSB, nor does it constitute financial product advice or take into account any individual's investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this presentation but must make its own assessment of NSB and conduct its own investigations. Before making an investment decision, investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. NSB is not licensed to provide financial product advice in respect of its securities or any other financial products. Cooling off rights do not apply to the acquisition of NSB securities.

Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of NSB, its officers, directors, employees and agents, nor any other person, accepts any responsibility and liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it. The information presented in this presentation is subject to change without notice and NSB does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation. The distribution of this presentation may be restricted by law and you should observe any such restrictions.

Forward Looking Statements

This presentation contains certain forward-looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. Such forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of NSB to be materially different from the results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the political and economic environment in which NSB will operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward-looking statements or other forecast. To the full extent permitted by law, NSB and its directors, officers, employees, advisers, agents and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation).